AVEVA
25.5.2023 10:26:27 CEST | Business Wire | Press release
AVEVA, a global leader in industrial software, has further strengthened its leadership team announcing four new senior executive roles as the company drives forward its new business model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005082/en/
Iju Raj, Executive Vice President of R&D, AVEVA (Photo: Business Wire)
The news follows the announcement in March of the company’s new Chief Executive Officer Caspar Herzberg, who took over the top job at AVEVA from Peter Herweck, now its chairperson. Herweck officially started as CEO of parent company Schneider Electric on May 4.
Sue Quense, currently AVEVA’s Senior Vice President of Americas, takes on the newly created role of Chief Commercial Officer. Quense, based in Philadelphia, USA, has spent more than three decades in software sales leadership roles. She was a driving force at OSIsoft, which merged with AVEVA in 2021 to meet the expanding industrial intelligence of global enterprises and accelerate the evolution of the connected industrial economy.
Marco Mueller, a long-time technology industry leader, joins AVEVA as Chief Marketing Officer and will be based in London, UK. He was formerly Senior Vice President Global Demand Marketing at ServiceNow, a leading cloud computing platform company headquartered in California’s Silicon Valley, for two and half years. Before that, Marco spent more than a decade in marketing executive roles with SAP, a market leader in enterprise application software where he led marketing teams across the globe. He began his career as a management consultant at Accenture in the high tech and consumer products industries.
With AVEVA’s goal to support end-to-end product innovation, the research & development (R&D) function and project delivery services will come together with the Business Units and Portfolio Management teams under the leadership of Rob McGreevy, Chief Product Officer.
Iju Raj, who has spent the last five years heading up AVEVA’s cloud platform, takes on the role of Executive Vice President for R&D and will report to McGreevy. Based in India, Raj will be responsible for the day-to-day leadership and operations of R&D, driving efficient development processes, programs, and software innovation.
Caspar Herzberg, CEO of AVEVA, said: “This is a pivotal moment in AVEVA’s 55-year heritage as a leading innovator of software and industrial sustainability. We are undergoing a portfolio-wide transition to a subscription-based business model, and I’m delighted to be adding such expertise and experience to the top table to further strengthen our growth plans.
“To accelerate access to modern solutions and meet dynamic business needs, customers can trade-in their existing perpetual licenses for subscriptions spanning any mix of cloud, hybrid, and on-premises solutions across the design-operate-optimize industrial lifecycle. Sue, Marco, Rob and Iju will be instrumental in further enhancing our leadership team and driving growth.”
- ENDS –
Notes to Editor
About AVEVA
AVEVA is a global leader in industrial software, sparking ingenuity to drive responsible use of the world’s resources. The company’s secure industrial cloud platform and applications enable businesses to harness the power of their information and improve collaboration with customers, suppliers, and partners.
Over 20,000 enterprises in over 100 countries rely on AVEVA to help them deliver life’s essentials: safe and reliable energy, food, medicines, infrastructure and more. By connecting people with trusted information and AI-enriched insights, AVEVA enables teams to engineer efficiently and optimize operations, driving growth and sustainability.
Named as one of the world’s most innovative companies, AVEVA supports customers with open solutions and the expertise of more than 6,400 employees, 5,000 partners and 5,700 certified developers. The company, which has operations around the globe, is headquartered in Cambridge, UK. Learn more at www.aveva.com.
Copyright © 2023 AVEVA Solutions Limited. All rights reserved. AVEVA Solutions Limited is owned by AVEVA Group. AVEVA, the AVEVA logos and AVEVA product names are trademarks or registered trademarks of AVEVA Group or its subsidiaries in the United Kingdom and other countries. Other brands and product- names are the trademarks of their respective companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom